Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CodeBreaK 200: sotorasib versus docetaxel in previously treated KRAS G12C-mutated NSCLC
NL-OMON59278Phase 3Completed
- Sponsor
- Amgen
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sotorasib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Amgen. Primary endpoint: Progression-free survival. Started May 2020; status: completed.
02
Drugs
sotorasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON59278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59278.